<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A high density of binding sites for the ligands 3H-SCH-23390 and 3H-SKF-83566 has been found in the choroid plexus </plain></SENT>
<SENT sid="1" pm="."><plain>Although these sites have similar pharmacology to D1 <z:chebi fb="40" ids="18243">dopamine</z:chebi> receptors, the high-affinity component of 3H-SCH-23390 binding in the choroid plexus has been identified as the 5-HT1c subtype of <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptor </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the possible role of these receptors in modulating the production of cerebrospinal fluid (CSF) in rats </plain></SENT>
<SENT sid="3" pm="."><plain>(R) SCH-23390 produced up to a 50% decrease in net CSF production, compared to saline </plain></SENT>
<SENT sid="4" pm="."><plain>This compound is a partial <z:chebi fb="4" ids="48705">agonist</z:chebi> at 5-HT1c <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptors, and an <z:chebi fb="68" ids="48706">antagonist</z:chebi> at D1 <z:chebi fb="40" ids="18243">dopamine</z:chebi> receptors </plain></SENT>
<SENT sid="5" pm="."><plain>The (S) enantiomer of SCH-23390 (SCH-23388) was ineffective </plain></SENT>
<SENT sid="6" pm="."><plain>Drugs interacting with receptors for <z:chebi fb="65" ids="25512">neurotransmitters</z:chebi> in the choroid plexus may hold promise for the treatment of patients with <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo>, including those with mass lesions, head trauma, <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000238'>hydrocephalus</z:hpo>, or <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> </plain></SENT>
</text></document>